Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Saved in:
Bibliographic Details
Title: Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Authors: Zhu L; Department of Endocrinology, Singapore General Hospital, Singapore., Cheung YM; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Chiang C; Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia., Gallagher EJ; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Hamnvik OR; Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Mammen J; Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins Medicine, Baltimore, Maryland, USA., Quandt Z; Medicine, Endocrinology, UCSF, San Francisco, California, USA., Jones R; Project Data Sphere LLC, Cary, North Carolina, USA., McDunn J; Project Data Sphere LLC, Morrisville, North Carolina, USA., Al-Bahadili H; Division of Endocrinology, Metabolism and Lipid Research, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Angell T; Division of Endocrinology and Diabetes, USC Keck School of Medicine, Los Angeles, California, USA., Bancos I; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA., Betof Warner A; Stanford University School of Medicine, Stanford, California, USA., Blackwell S; Duke Cancer Institute, Durham, North Carolina, USA., Calabrese C; Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA., Cho TA; The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA., Dougan M; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA., Ferreira M; Johns Hopkins Medicine, Baltimore, Maryland, USA., Funchain P; Stanford University School of Medicine, Stanford, California, USA., Herndon J; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Kennedy R; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Kheterpal M; Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA., Khouri M; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA., Lechner MG; Division of Endocrinology, Diabetes, and Metabolism, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA., Lim AM; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Markova A; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Meara A; Division of Oncology, The Ohio State University, Columbus, Ohio, USA., Overton L; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Perdigoto AL; Yale University Department of Medical Oncology, New Haven, Connecticut, USA., Sachithanandan N; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Sharon E; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Spain L; Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Tsai K; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Yarchoan M; Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA., Reynolds KL; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., Shariff A; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA afreen.shariff@duke.edu.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Oct 15; Vol. 13 (10). Date of Electronic Publication: 2025 Oct 15.
Publication Type: Consensus Statement; Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-011865